GSK Acquires Syndivia's Prostate Cancer ADC
GSK has acquired the rights to Syndivia's preclinical antibody drug conjugate (ADC) for prostate cancer treatment.
Despite having its own ADC in development for prostate cancer, GSK is investing in Syndivia's ADC, fueling industry buzz for the promising anti-tumor modality.
The gold standard of business intelligence.
GSK's acquisition is valued at £268m.
Author's summary: GSK buys Syndivia's prostate cancer ADC for £268m.
More News
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Victorian Access Regime: VicGrid’s new regime for ... | Clayton Utz
- English Dub Review: Gachiakuta “The Storm Before The Storm” - Bubbleblabber
- ‘Dracula’ comes to PiM Arts with secrets, stakes and a whole lot of blood - Eden Prairie Local News
- Tariffs Shake Canadian Produce Supply Chain